In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers.
Emmanuelle Andree Danielle SchindlerAshley M Schnakenberg MartinR Andrew SewellMohini RanganathanAnna DeForestBrian P PittmanAlbert PerrinoDeepak C D'SouzaPublished in: Psychopharmacology (2020)
In this exploratory controlled study, intravenous THC lacked significant antinociceptive properties in experimental models of acute pain and capsaicin-induced hyperalgesia in healthy human subjects. Continued study of THC and other cannabinoids through high-quality, controlled studies in both healthy volunteers and patients with pain conditions is warranted to inform the growing demand for the clinical application of cannabinoids in pain management.
Keyphrases
- pain management
- placebo controlled
- double blind
- chronic pain
- endothelial cells
- neuropathic pain
- phase iii
- clinical trial
- high dose
- phase ii
- study protocol
- open label
- spinal cord
- pluripotent stem cells
- hepatitis b virus
- extracorporeal membrane oxygenation
- diabetic rats
- aortic dissection
- acute respiratory distress syndrome